Filing Flows

Filing Flows › Companies › Ginkgo Bioworks Holdings › Cash flow

Ginkgo Bioworks Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$46.9M in Q2 2026 · −$175M over twelve months

Operating cash flow−$44.3M
Capital spending−$2.6M
Free cash flow−$46.9M
Cash conversion cycle-611 days

Analysis

In Q2 2026, Ginkgo Bioworks Holdings generated −$44.3M of operating cash flow and spent $2.6M on capital projects, leaving free cash flow of −$46.9M. That is $6.6M less than in Q2 2025 (−$40.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$170M; the largest uses were operating cash flow ($170M), capital spending ($4.6M), other financing ($1.9M); besides operations, cash came from other investing ($61.1M), shares issued ($36.5M); the cash balance fell by $79.3M.

Operating cash flow was −$44.3M against net income of −$46.7M. The largest differences: depreciation & amortization +$12.3M, stock-based pay +$7.6M, prepaid and other assets −$6.7M.

Its cash conversion cycle was -611 days (receivables 74 + inventory 0 − payables 685): suppliers fund its working capital.

Free cash flow

Ginkgo Bioworks Holdings: free cash flow by quarterGinkgo Bioworks Holdings: free cash flow by quarter−$119MQ3 2024−$56.1MQ4 2024−$59.1MQ1 2025−$40.3MQ2 2025−$31.6MQ3 2025−$47.7MQ4 2025−$48.6MQ1 2026−$46.9MQ2 2026
Operating cash flow less capital spending.
Ginkgo Bioworks Holdings: operating cash flow against capital spendingGinkgo Bioworks Holdings: operating cash flow against capital spendingOperating cash flowCapital spending−$104M$15.1MQ3 2024−$42.4M$13.7MQ4 2024−$51.5M$7.6MQ1 2025−$40.3M$38KQ2 2025−$31.6M$0Q3 2025−$47.7M$5KQ4 2025−$46.7M$1.9MQ1 2026−$44.3M$2.6MQ2 2026
Latest (Q2 2026): Operating cash flow −$44.3M, Capital spending $2.6M.

Capital allocation, year by year

Ginkgo Bioworks Holdings: where the cash came from (up) and went (down), by fiscal yearGinkgo Bioworks Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$254MFY2021: Net borrowing −$1.1MFY2021: Shares issued $15.1MFY2021: Capital spending −$56.5MFY2021: Acquisitions −$12.0MFY2021: Buybacks −$25.0M$15.1MFY2021FY2022: Operating cash flow −$252MFY2022: Net borrowing $98.1MFY2022: Shares issued $40.4MFY2022: Capital spending −$52.3MFY2022: Acquisitions $82.4M$221MFY2022FY2023: Operating cash flow −$296MFY2023: Net borrowing −$1.3MFY2023: Shares issued $93KFY2023: Asset sales $4.4MFY2023: Capital spending −$40.8M$4.5MFY2023FY2024: Operating cash flow −$320MFY2024: Net borrowing −$897KFY2024: Shares issued $84KFY2024: Asset sales $648KFY2024: Capital spending −$62.5MFY2024: Acquisitions −$5.4M$732KFY2024FY2025: Operating cash flow −$171MFY2025: Net borrowing −$354KFY2025: Shares issued $19.5MFY2025: Asset sales $574KFY2025: Capital spending −$7.7M$20.0MFY2025
Over these 5 years operating cash flow totalled −$1.3B; the largest uses were operating cash flow ($1.3B) and capital spending ($220M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$340M
Debtnone
Net cash$340M
Cash runway23 months

Ginkgo Bioworks Holdings is burning cash: its operations consume cash, a free cash flow of −$175M a year at the current rate against $340M of cash and investments: a runway of about 23 months before any new financing.

Where the cash came from and went

Ginkgo Bioworks Holdings: sources (+) and uses (−) of cash, Q2 2026Ginkgo Bioworks Holdings: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$44.3MCash drawn (+) / kept (−)$16.7MOther financing$16.5MOther investing$13.7MCapital spending−$2.6MExchange rates$43K
Ginkgo Bioworks Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Ginkgo Bioworks Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$170MCash drawn (+) / kept (−)$79.3MOther investing$61.1MShares issued$36.5MCapital spending−$4.6MOther financing−$1.9MExchange rates−$145KNet borrowing (+) / repaid (−)−$68K

From profit to cash

Ginkgo Bioworks Holdings: net income to operating cash flow, Q2 2026Ginkgo Bioworks Holdings: net income to operating cash flow, Q2 2026Net income−$46.7MDepreciation & amortization$12.3MStock-based pay$7.6MGains on investments−$2.0MOther non-cash−$474KReceivables$3.7MDeferred revenue−$3.0MPrepaid and other assets−$6.7MOther liabilities−$5.4MOperating cash flow−$44.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202674—685-611
Q1 2026101—390-289

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$44.3M−$2.6M——$16.7M−$46.9M
Q1 2026−$46.7M−$1.9M−$19K—$23.7M−$48.6M
Q4 2025−$47.7M−$5K−$25K$9.2M−$55.4M−$47.7M
Q3 2025−$31.6M—−$24K$10.3M$94.4M−$31.6M
Q2 2025−$40.3M−$38K−$98K—$104M−$40.3M
Q1 2025−$51.5M−$7.6M−$207K—$250M−$59.1M
Q4 2024−$42.4M−$13.7M−$203K—$55.8M−$56.1M
Q3 2024−$104M−$15.1M−$200K—$114M−$119M

Ginkgo Bioworks Holdings: income statement and cash flow

Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%. The chart follows the revenue to costs, profit and cash.

Ginkgo Bioworks Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.